Back to Search
Start Over
Gut microbiota-derived short-chain fatty acids and kidney diseases.
- Source :
-
Drug design, development and therapy [Drug Des Devel Ther] 2017 Dec 11; Vol. 11, pp. 3531-3542. Date of Electronic Publication: 2017 Dec 11 (Print Publication: 2017). - Publication Year :
- 2017
-
Abstract
- Gut microbiota and its metabolites play pivotal roles in host physiology and pathology. Short-chain fatty acids (SCFAs), as a group of metabolites, exert positive regulatory effects on energy metabolism, hormone secretion, immune inflammation, hypertension, and cancer. The functions of SCFAs are related to their activation of transmembrane G protein-coupled receptors and their inhibition of histone acetylation. Though controversial, growing evidence suggests that SCFAs, which regulate inflammation, oxidative stress, and fibrosis, have been involved in kidney disease through the activation of the gut-kidney axis; however, the molecular relationship among gut microbiota-derived metabolites, signaling pathways, and kidney disease remains to be elucidated. This review will provide an overview of the physiology and functions of SCFAs in kidney disease.<br />Competing Interests: Disclosure The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest in this work.
Details
- Language :
- English
- ISSN :
- 1177-8881
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Drug design, development and therapy
- Publication Type :
- Academic Journal
- Accession number :
- 29270002
- Full Text :
- https://doi.org/10.2147/DDDT.S150825